Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 211920, held by Gland. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 211920 (Phenylephrine Hydrochloride), held by Gland, was first approved by FDA on Jun 5, 2020, with 0 approved supplements and 0 published complete response letters.
Phenylephrine hydrochloride injection, 10 mg/mL, is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2020 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters